IBDEI0VR ; ; 09-AUG-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41704,2)
 ;;=^5133322
 ;;^UTILITY(U,$J,358.3,41705,0)
 ;;=C34.81^^124^1802^6
 ;;^UTILITY(U,$J,358.3,41705,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41705,1,3,0)
 ;;=3^Malignant neoplasm of ovrlp sites of right bronchus and lung
 ;;^UTILITY(U,$J,358.3,41705,1,4,0)
 ;;=4^C34.81
 ;;^UTILITY(U,$J,358.3,41705,2)
 ;;=^5000964
 ;;^UTILITY(U,$J,358.3,41706,0)
 ;;=C34.82^^124^1802^5
 ;;^UTILITY(U,$J,358.3,41706,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41706,1,3,0)
 ;;=3^Malignant neoplasm of ovrlp sites of left bronchus and lung
 ;;^UTILITY(U,$J,358.3,41706,1,4,0)
 ;;=4^C34.82
 ;;^UTILITY(U,$J,358.3,41706,2)
 ;;=^5000965
 ;;^UTILITY(U,$J,358.3,41707,0)
 ;;=C83.38^^124^1803^22
 ;;^UTILITY(U,$J,358.3,41707,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41707,1,3,0)
 ;;=3^Diffuse large B-cell lymphoma, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,41707,1,4,0)
 ;;=4^C83.38
 ;;^UTILITY(U,$J,358.3,41707,2)
 ;;=^5001579
 ;;^UTILITY(U,$J,358.3,41708,0)
 ;;=C83.58^^124^1803^29
 ;;^UTILITY(U,$J,358.3,41708,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41708,1,3,0)
 ;;=3^Lymphoblastic (diffuse) lymphoma, lymph nodes mult site
 ;;^UTILITY(U,$J,358.3,41708,1,4,0)
 ;;=4^C83.58
 ;;^UTILITY(U,$J,358.3,41708,2)
 ;;=^5001589
 ;;^UTILITY(U,$J,358.3,41709,0)
 ;;=C83.78^^124^1803^15
 ;;^UTILITY(U,$J,358.3,41709,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41709,1,3,0)
 ;;=3^Burkitt lymphoma, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,41709,1,4,0)
 ;;=4^C83.78
 ;;^UTILITY(U,$J,358.3,41709,2)
 ;;=^5001599
 ;;^UTILITY(U,$J,358.3,41710,0)
 ;;=C83.18^^124^1803^35
 ;;^UTILITY(U,$J,358.3,41710,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41710,1,3,0)
 ;;=3^Mantle cell lymphoma, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,41710,1,4,0)
 ;;=4^C83.18
 ;;^UTILITY(U,$J,358.3,41710,2)
 ;;=^5001569
 ;;^UTILITY(U,$J,358.3,41711,0)
 ;;=C83.38^^124^1803^23
 ;;^UTILITY(U,$J,358.3,41711,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41711,1,3,0)
 ;;=3^Diffuse large B-cell lymphoma, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,41711,1,4,0)
 ;;=4^C83.38
 ;;^UTILITY(U,$J,358.3,41711,2)
 ;;=^5001579
 ;;^UTILITY(U,$J,358.3,41712,0)
 ;;=C84.68^^124^1803^12
 ;;^UTILITY(U,$J,358.3,41712,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41712,1,3,0)
 ;;=3^Anaplastic large cell lymphoma, ALK-pos, nodes mult site
 ;;^UTILITY(U,$J,358.3,41712,1,4,0)
 ;;=4^C84.68
 ;;^UTILITY(U,$J,358.3,41712,2)
 ;;=^5001659
 ;;^UTILITY(U,$J,358.3,41713,0)
 ;;=C84.78^^124^1803^11
 ;;^UTILITY(U,$J,358.3,41713,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41713,1,3,0)
 ;;=3^Anaplastic large cell lymphoma, ALK-neg, nodes mult site
 ;;^UTILITY(U,$J,358.3,41713,1,4,0)
 ;;=4^C84.78
 ;;^UTILITY(U,$J,358.3,41713,2)
 ;;=^5001669
 ;;^UTILITY(U,$J,358.3,41714,0)
 ;;=C81.08^^124^1803^43
 ;;^UTILITY(U,$J,358.3,41714,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41714,1,3,0)
 ;;=3^Nodular lymphocyte predom Hodgkin lymphoma, nodes mult site
 ;;^UTILITY(U,$J,358.3,41714,1,4,0)
 ;;=4^C81.08
 ;;^UTILITY(U,$J,358.3,41714,2)
 ;;=^5001399
 ;;^UTILITY(U,$J,358.3,41715,0)
 ;;=C81.48^^124^1803^28
 ;;^UTILITY(U,$J,358.3,41715,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41715,1,3,0)
 ;;=3^Lymp-rich classical Hodgkin lymphoma, lymph nodes mult site
 ;;^UTILITY(U,$J,358.3,41715,1,4,0)
 ;;=4^C81.48
 ;;^UTILITY(U,$J,358.3,41715,2)
 ;;=^5001439
 ;;^UTILITY(U,$J,358.3,41716,0)
 ;;=C81.18^^124^1803^44
 ;;^UTILITY(U,$J,358.3,41716,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41716,1,3,0)
 ;;=3^Nodular sclerosis class Hodgkin lymphoma, nodes mult site
 ;;^UTILITY(U,$J,358.3,41716,1,4,0)
 ;;=4^C81.18
 ;;^UTILITY(U,$J,358.3,41716,2)
 ;;=^5001409
 ;;^UTILITY(U,$J,358.3,41717,0)
 ;;=C81.28^^124^1803^36
 ;;^UTILITY(U,$J,358.3,41717,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41717,1,3,0)
 ;;=3^Mixed cellular classical Hodgkin lymphoma, nodes mult site
 ;;^UTILITY(U,$J,358.3,41717,1,4,0)
 ;;=4^C81.28
 ;;^UTILITY(U,$J,358.3,41717,2)
 ;;=^5001419
 ;;^UTILITY(U,$J,358.3,41718,0)
 ;;=C81.38^^124^1803^30
 ;;^UTILITY(U,$J,358.3,41718,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41718,1,3,0)
 ;;=3^Lymphocy depleted class Hodgkin lymphoma, nodes mult site
 ;;^UTILITY(U,$J,358.3,41718,1,4,0)
 ;;=4^C81.38
 ;;^UTILITY(U,$J,358.3,41718,2)
 ;;=^5001429
 ;;^UTILITY(U,$J,358.3,41719,0)
 ;;=C82.98^^124^1803^26
 ;;^UTILITY(U,$J,358.3,41719,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41719,1,3,0)
 ;;=3^Follicular lymphoma, unsp, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,41719,1,4,0)
 ;;=4^C82.98
 ;;^UTILITY(U,$J,358.3,41719,2)
 ;;=^5001549
 ;;^UTILITY(U,$J,358.3,41720,0)
 ;;=C84.08^^124^1803^42
 ;;^UTILITY(U,$J,358.3,41720,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41720,1,3,0)
 ;;=3^Mycosis fungoides, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,41720,1,4,0)
 ;;=4^C84.08
 ;;^UTILITY(U,$J,358.3,41720,2)
 ;;=^5001629
 ;;^UTILITY(U,$J,358.3,41721,0)
 ;;=C84.18^^124^1803^48
 ;;^UTILITY(U,$J,358.3,41721,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41721,1,3,0)
 ;;=3^Sezary disease, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,41721,1,4,0)
 ;;=4^C84.18
 ;;^UTILITY(U,$J,358.3,41721,2)
 ;;=^5001639
 ;;^UTILITY(U,$J,358.3,41722,0)
 ;;=C91.40^^124^1803^27
 ;;^UTILITY(U,$J,358.3,41722,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41722,1,3,0)
 ;;=3^Hairy cell leukemia not having achieved remission
 ;;^UTILITY(U,$J,358.3,41722,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,41722,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,41723,0)
 ;;=C96.0^^124^1803^39
 ;;^UTILITY(U,$J,358.3,41723,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41723,1,3,0)
 ;;=3^Multifocal and multisystemic Langerhans-cell histiocytosis
 ;;^UTILITY(U,$J,358.3,41723,1,4,0)
 ;;=4^C96.0
 ;;^UTILITY(U,$J,358.3,41723,2)
 ;;=^5001859
 ;;^UTILITY(U,$J,358.3,41724,0)
 ;;=C96.2^^124^1803^34
 ;;^UTILITY(U,$J,358.3,41724,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41724,1,3,0)
 ;;=3^Malignant mast cell tumor
 ;;^UTILITY(U,$J,358.3,41724,1,4,0)
 ;;=4^C96.2
 ;;^UTILITY(U,$J,358.3,41724,2)
 ;;=^5001860
 ;;^UTILITY(U,$J,358.3,41725,0)
 ;;=C84.48^^124^1803^45
 ;;^UTILITY(U,$J,358.3,41725,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41725,1,3,0)
 ;;=3^Peripheral T-cell lymphoma, not classified, nodes mult site
 ;;^UTILITY(U,$J,358.3,41725,1,4,0)
 ;;=4^C84.48
 ;;^UTILITY(U,$J,358.3,41725,2)
 ;;=^5001649
 ;;^UTILITY(U,$J,358.3,41726,0)
 ;;=C90.01^^124^1803^41
 ;;^UTILITY(U,$J,358.3,41726,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41726,1,3,0)
 ;;=3^Multiple myeloma in remission
 ;;^UTILITY(U,$J,358.3,41726,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,41726,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,41727,0)
 ;;=C90.02^^124^1803^40
 ;;^UTILITY(U,$J,358.3,41727,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41727,1,3,0)
 ;;=3^Multiple myeloma in relapse
 ;;^UTILITY(U,$J,358.3,41727,1,4,0)
 ;;=4^C90.02
 ;;^UTILITY(U,$J,358.3,41727,2)
 ;;=^5001753
 ;;^UTILITY(U,$J,358.3,41728,0)
 ;;=C90.11^^124^1803^47
 ;;^UTILITY(U,$J,358.3,41728,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41728,1,3,0)
 ;;=3^Plasma cell leukemia in remission
 ;;^UTILITY(U,$J,358.3,41728,1,4,0)
 ;;=4^C90.11
 ;;^UTILITY(U,$J,358.3,41728,2)
 ;;=^267517
 ;;^UTILITY(U,$J,358.3,41729,0)
 ;;=C90.12^^124^1803^46
 ;;^UTILITY(U,$J,358.3,41729,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41729,1,3,0)
 ;;=3^Plasma cell leukemia in relapse
 ;;^UTILITY(U,$J,358.3,41729,1,4,0)
 ;;=4^C90.12
 ;;^UTILITY(U,$J,358.3,41729,2)
 ;;=^5001755
 ;;^UTILITY(U,$J,358.3,41730,0)
 ;;=C90.21^^124^1803^25
 ;;^UTILITY(U,$J,358.3,41730,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41730,1,3,0)
 ;;=3^Extramedullary plasmacytoma in remission
 ;;^UTILITY(U,$J,358.3,41730,1,4,0)
 ;;=4^C90.21
 ;;^UTILITY(U,$J,358.3,41730,2)
 ;;=^5001757
 ;;^UTILITY(U,$J,358.3,41731,0)
 ;;=C90.31^^124^1803^50
 ;;^UTILITY(U,$J,358.3,41731,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41731,1,3,0)
 ;;=3^Solitary plasmacytoma in remission
 ;;^UTILITY(U,$J,358.3,41731,1,4,0)
 ;;=4^C90.31
 ;;^UTILITY(U,$J,358.3,41731,2)
 ;;=^5001760
 ;;^UTILITY(U,$J,358.3,41732,0)
 ;;=C88.8^^124^1803^33
 ;;^UTILITY(U,$J,358.3,41732,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41732,1,3,0)
 ;;=3^Malignant immunoproliferative diseases NEC
 ;;^UTILITY(U,$J,358.3,41732,1,4,0)
 ;;=4^C88.8
 ;;^UTILITY(U,$J,358.3,41732,2)
 ;;=^5001750
 ;;^UTILITY(U,$J,358.3,41733,0)
 ;;=C90.22^^124^1803^24
 ;;^UTILITY(U,$J,358.3,41733,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41733,1,3,0)
 ;;=3^Extramedullary plasmacytoma in relapse
 ;;^UTILITY(U,$J,358.3,41733,1,4,0)
 ;;=4^C90.22
 ;;^UTILITY(U,$J,358.3,41733,2)
 ;;=^5001758
 ;;^UTILITY(U,$J,358.3,41734,0)
 ;;=C90.32^^124^1803^49
 ;;^UTILITY(U,$J,358.3,41734,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41734,1,3,0)
 ;;=3^Solitary plasmacytoma in relapse
 ;;^UTILITY(U,$J,358.3,41734,1,4,0)
 ;;=4^C90.32
 ;;^UTILITY(U,$J,358.3,41734,2)
 ;;=^5001761
 ;;^UTILITY(U,$J,358.3,41735,0)
 ;;=C91.01^^124^1803^2
 ;;^UTILITY(U,$J,358.3,41735,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41735,1,3,0)
 ;;=3^Acute lymphoblastic leukemia, in remission
 ;;^UTILITY(U,$J,358.3,41735,1,4,0)
 ;;=4^C91.01
 ;;^UTILITY(U,$J,358.3,41735,2)
 ;;=^5001763
 ;;^UTILITY(U,$J,358.3,41736,0)
 ;;=C91.02^^124^1803^1
 ;;^UTILITY(U,$J,358.3,41736,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41736,1,3,0)
 ;;=3^Acute lymphoblastic leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,41736,1,4,0)
 ;;=4^C91.02
 ;;^UTILITY(U,$J,358.3,41736,2)
 ;;=^5001764
 ;;^UTILITY(U,$J,358.3,41737,0)
 ;;=C91.11^^124^1803^16
 ;;^UTILITY(U,$J,358.3,41737,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41737,1,3,0)
 ;;=3^Chronic lymphocytic leukemia of B-cell type in remission
 ;;^UTILITY(U,$J,358.3,41737,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,41737,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,41738,0)
 ;;=C91.12^^124^1803^17
 ;;^UTILITY(U,$J,358.3,41738,1,0)
 ;;=^358.31IA^4^2
